These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28239869)

  • 1. Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease.
    Ward MG; Thwaites PA; Beswick L; Hogg J; Rosella G; Van Langenberg D; Reynolds J; Gibson PR; Sparrow MP
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1135-1145. PubMed ID: 28239869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
    Assa A; Matar M; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Shamir R
    Gastroenterology; 2019 Oct; 157(4):985-996.e2. PubMed ID: 31194979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.
    Ward MG; Warner B; Unsworth N; Chuah SW; Brownclarke C; Shieh S; Parkes M; Sanderson JD; Arkir Z; Reynolds J; Gibson PR; Irving PM
    Aliment Pharmacol Ther; 2017 Jul; 46(2):150-161. PubMed ID: 28481014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis.
    Little RD; Chu IE; van der Zanden EP; Flanagan E; Bell SJ; Gibson PR; Sparrow MP; Shelton E; Connor SJ; Roblin X; Ward MG
    J Crohns Colitis; 2019 Dec; 13(12):1527-1536. PubMed ID: 31094417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease.
    Zittan E; Steinhart AH; Goldstein P; Milgrom R; Gralnek IM; Silverberg MS
    Clin Transl Gastroenterol; 2021 Oct; 12(10):e00401. PubMed ID: 34613952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
    Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
    Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.
    Zittan E; Kabakchiev B; Milgrom R; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    J Crohns Colitis; 2016 May; 10(5):510-5. PubMed ID: 26783345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
    Bond A; Asher R; Jackson R; Sager K; Martin K; Kneebone A; Philips S; Taylor W; Subramanian S
    Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):271-6. PubMed ID: 26657455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
    Nakase H; Motoya S; Matsumoto T; Watanabe K; Hisamatsu T; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    Aliment Pharmacol Ther; 2017 Nov; 46(9):873-882. PubMed ID: 28884856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease.
    Morita Y; Imaeda H; Nishida A; Inatomi O; Bamba S; Sasaki M; Tsujikawa T; Sugimoto M; Andoh A
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1831-1836. PubMed ID: 27043158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission.
    Plevris N; Lyons M; Jenkinson PW; Chuah CS; Merchant LM; Pattenden RJ; Watson EF; Ho GT; Noble CL; Shand AG; Din S; Arnott ID; Jones GR; Lees CW
    Inflamm Bowel Dis; 2019 May; 25(6):1036-1043. PubMed ID: 30335139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease.
    Mazor Y; Almog R; Kopylov U; Ben Hur D; Blatt A; Dahan A; Waterman M; Ben-Horin S; Chowers Y
    Aliment Pharmacol Ther; 2014 Sep; 40(6):620-8. PubMed ID: 25039584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease.
    Ungar B; Ben-Shatach Z; Selinger L; Malik A; Albshesh A; Ben-Horin S; Eliakim R; Kopylov U; Carter D
    United European Gastroenterol J; 2020 Mar; 8(2):167-174. PubMed ID: 32213067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease.
    Bodini G; Giannini EG; Furnari M; Marabotto E; Baldissarro I; Del Nero L; Assandri L; Moscatelli A; Savarino V; Savarino E
    J Gastrointestin Liver Dis; 2015 Dec; 24(4):451-6. PubMed ID: 26697571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
    Vande Casteele N; Baert F; Bian S; Dreesen E; Compernolle G; Van Assche G; Ferrante M; Vermeire S; Gils A
    J Crohns Colitis; 2019 Sep; 13(10):1248-1256. PubMed ID: 30820530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
    Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
    Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study.
    Ungar B; Engel T; Yablecovitch D; Lahat A; Lang A; Avidan B; Har-Noy O; Carter D; Levhar N; Selinger L; Neuman S; Natour OH; Yavzori M; Fudim E; Picard O; Kopylov U; Chowers Y; Naftali T; Broide E; Shachar E; Eliakim R; Ben-Horin S
    Am J Gastroenterol; 2018 Jun; 113(6):890-898. PubMed ID: 29867175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE
    Scand J Gastroenterol; 2016; 51(4):442-7. PubMed ID: 26595391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher Maintenance Adalimumab Trough Levels are Associated With Achievement of Advanced Remission Targets in Patients With Inflammatory Bowel Disease.
    Ritter E; Hirsch A; Isakov NF; Ron Y; Cohen NA; Maharshak N
    J Clin Gastroenterol; 2021 Oct; 55(9):810-814. PubMed ID: 33060434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.